Demystify drug coverage. Learn the business and clinical reasons why some medications are covered by insurance and others ...

Investing.com - TD Cowen has lowered its price target on Novo Nordisk (NYSE: NVO) to $70.00 from $105.00 while maintaining a Buy rating on the stock. The new target sits within the broader analyst ...

A draft copy of an upcoming MAHA report reveals a strategy in lockstep with recent HHS actions such as reviving the Task ...

Novo Nordisk announced Monday that US patients can now get a month’s supply of Ozempic, the blockbuster diabetes drug, for ...

Novo Nordisk and GoodRx announced a partnership this week to sell products Ozempic and Wegovy at half their normal cost to ...

This week, medication savings platform GoodRx announced a partnership with Novo Nordisk – the company behind Ozempic and ...

The Texas Rangers are going to skip Jacob deGrom’s scheduled start this week because of shoulder fatigue, but the club said it is merely managing his workload and he ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Pediatric group bucks RFK Jr. on kids’ COVID-19 shots In a shift away from Department of ...

Welcome to The Hill’s Business & Economy newsletter{beacon} Business & Economy Business & Economy   The Big Story Trump admin ...

Novo Nordisk lowers Ozempic cost to $499 per month for uninsured U.S. patients, expanding access through NovoCare and 70,000 ...

What To Know: Under the agreement, all strengths of the medications will now be available to eligible self-paying patients at $499 per month through GoodRx's platform.

GoodRx reports that insurance formularies are shrinking, leading to fewer covered medications and increased restrictions on ...